This is a news story, published by Gizmodo, that relates primarily to McGill University news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Gizmodo, you can click here:
more news from GizmodoOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
best obesity treatments. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other related obesity treatments news, Ozempic news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
obesity treatmentGizmodo
•
72% Informative
Researchers at McGill University reviewed clinical trials of GLP-1 drugs like Ozempic and Wegovy .
They reaffirmed the safety and effectiveness of today ’s drugs.
But they highlighted the potential superiority of newer compounds such as retatrutide, which has helped people lose more than 20% of their original body weight in trials.
Whether that actually happens, we’ll have to see. But it’s almost certain that there will be plenty of drugs coming for semaglutide and tirzepatide’s current crown as the best obesity treatments around..
VR Score
68
Informative language
69
Neutral language
49
Article tone
informal
Language
English
Language complexity
59
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links